Press Release

HeartFlow, Leader in Revolutionizing Precision Heart Care, Closes $215 Million in Series F Funding Led by Bain Capital Life Sciences

Financing will further drive commercial scale for HeartFlow’s AI-enabled portfolio of precision heart care products

MOUNTAIN VIEW, Calif. – April 6, 2023 — HeartFlow, Inc., the leader in revolutionizing precision heart care, today announced the close of a $215 million Series F funding round by its parent company, HeartFlow Holding, Inc. led by Bain Capital Life Sciences with participation from new investor, Janus Henderson Investors, and existing investors, including Baillie Gifford, Capricorn Investment Group, Hayfin Capital Management, HealthCor, Martis Capital, USVP and Wellington Management. This new funding will enable HeartFlow to meet the growing demand for its commercial products, support a robust body of growing clinical evidence and advance its comprehensive product portfolio to help physicians to diagnose coronary artery disease(CAD) and guide their treatment decisions.

The financing follows a period of remarkable growth for HeartFlow. Coronary computed tomography angiography (CCTA) and FFRCT have already been recognized by the recent ACC/AHA Chest Pain Guidelines, and HeartFlow’s FFRCT technology is covered by 100% of Medicare and over 98% of commercial payers. With the recent FDA clearance of new products, the company is the first and only company to provide non-invasive coronary artery anatomy (RoadMap analysis), physiology(HeartFlow® FFRCT), and plaque information (Plaque analysis) based on CCTA. These products enable physicians to gain more understanding of a patient’s CAD and are the most comprehensive approach to predict risk of a heart attack.1

“HeartFlow has built a strong intellectual property portfolio, brought to market the only combined anatomy, physiology, and plaque analysis to help diagnose and treat heart disease, and is now in over 725 hospital systems worldwide with over 180,000 patients served to date,” said John Farquhar, Chief Executive Officer of HeartFlow. “The oversubscription of our Series F funding round, particularly in the current market backdrop, is a strong validation of our technology, our team, and the opportunity in front of us. We appreciate the support of our investors, both existing and new, who share HeartFlow’s vision to build a new standard of care for people at risk of heart disease.”

“HeartFlow is a leader in precision heart care and its AI-enabled products promise to help physicians more effectively diagnose and treat heart disease, which continues to be the leading cause of death in the U.S.,” said Nicholas Downing, M.D., a Managing Director at Bain Capital Life Sciences. “We look forward to supporting the company’s commitment to improving cardiovascular care for patients as it heads into this exciting next chapter of growth.”

The HeartFlow product pipeline is expected to continue to propel the company’s position as a precision diagnostics leader. HeartFlow’s additional product launches will enable the company to further support physicians in their commitment to improve cardiovascular patient outcomes.

J.P. Morgan acted as sole placement agent to HeartFlow.


About HeartFlow

HeartFlow is the global leader in revolutionizing precision heart care, uniquely combining human ingenuity with advanced AI technology. Headquartered in Mountain View, California, our technology has been published in more than 500 peer-reviewed publications that showcase the value of anatomy, physiology, and plaque. We began our journey to improve CAD diagnosis with FFRCT and have now expanded our product portfolio to include anatomic stenosis and plaque information. To date, clinicians have used our technology for over 180,000 patients to aid in the diagnosis of heart disease. For more information, visit and connect on Twitter and LinkedIn.


Linly Ku

  1. Emerald I – Lee, et al. JACC Imaging 2019.

Contact Us

*Required fields

Request the HeartFlow Analysis Near You

If you would like to request to have the HeartFlow Analysis available at a location near you, please submit your information below with details of the institution. We will share this information with the institution, but it will not guarantee HeartFlow will become available.

*Required fields

残念ながら、GDPR 規制により、この Web フォームを通じて求人への応募やキャリアに関する問い合わせを受け付けることはできません。弊社を通じてお申込みください 採用ページ. ご関心をお寄せいただきありがとうございます!


HeartFlow FFRCT 分析は、有資格の臨床医による臨床的に安定した症状のある冠状動脈疾患患者への使用を目的とした個別化された心臓検査です。 HeartFlow Analysis によって提供される情報は、資格のある臨床医が患者の病歴、症状、その他の診断検査、および臨床医の専門的判断と組み合わせて使用​​することを目的としています。


さらに質問がある場合は、このメッセージを閉じてフォームに記入するか、サポート チームにお電話ください。: 877.478.3569.

The HeartFlow FFRCT Analysis is a personalized cardiac test indicated for use in clinically stable symptomatic patients with coronary artery disease by qualified clinicians. The information provided by the HeartFlow Analysis is intended to be used by qualified clinicians in conjunction with the patient’s history, symptoms, and other diagnostic tests, as well as the clinician’s professional judgement.

For additional indication information about the HeartFlow Analysis, please visit

If you have additional questions, close out of this message to complete our form or call our support team: 877.478.3569.

Please apply for research grants through our online submission form.

Unfortunately, we cannot take job applications or career inquiries through this web form due to GDPR regulations. Please apply through our Careers Page. Thank you for your interest!

Campbell Rogers, M.D., F.A.C.C.

Executive Vice President and Chief Medical Officer

Campbell brings a wealth of experience to HeartFlow, where he serves as the Chief Medical Officer. Prior to joining HeartFlow, he was the Chief Scientific Officer and Global Head of Research and Development at Cordis Corporation, Johnson & Johnson, where he was responsible for leading investments and research in cardiovascular devices. Prior to Cordis, he was Associate Professor of Medicine at Harvard Medical School and the Harvard-M.I.T. Division of Health Sciences and Technology, and Director of the Cardiac Catheterization and Experimental Cardiovascular Interventional Laboratories at Brigham and Women’s Hospital. He served as Principal Investigator for numerous interventional cardiology device, diagnostic, and pharmacology trials, is the author of numerous journal articles, chapters, and books in the area of coronary artery and other cardiovascular diseases, and was the recipient of research grant awards from the NIH and AHA.

He received his A.B. from Harvard College and his M.D. from Harvard Medical School.